Abstract
No public abstract is available from the verified source records.
Maryam Bibi, Rabia Arshad, Shaneel Kousar, Gul-e-Maryam, Javed Iqbal, Anam Fatima, Rida Siddique, Ansa Ashfaq
Abstract
Authors
Institutions
No local reference links have been materialized yet.
No local citing links have been materialized yet.
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
2024
Chronic kidney disease
10.1016/s0140-6736(21)00519-5 · 2021
Chronic kidney disease
2025
Role of TGF-β in chronic kidney disease: an integration of tubular, glomerular and vascular effects
10.1007/s00441-011-1275-6 · 2012
Where are they now: spatial and molecular diversity of tissue-resident macrophages in the kidney
10.1016/j.semnephrol.2022.10.002 · 2022
National trends and projection of chronic kidney disease incidence according to etiology from 1990 to 2030 in Iran: a Bayesian age-period-cohort modeling study
10.4178/epih.e2023027 · 2023
Chronic kidney disease and the global public health agenda: an international consensus
10.1038/s41581-024-00820-6 · 2024
Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients--absence of evidence or evidence of absence?
10.2215/cjn.03740907 · 2008
SARS-CoV-2 causes a specific dysfunction of the kidney proximal tubule
10.1016/j.kint.2020.07.019 · 2020
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
openalex
Confidence 95%
datacite
Confidence 0%
TGF-β1 signaling: immune dynamics of chronic kidney diseases
10.3389/fmed.2021.628519 · 2021
GFR estimation: from physiology to public health
10.1053/j.ajkd.2013.12.006 · 2014
Promoting plant-based therapies for chronic kidney disease
10.1177/2515690x221079688 · 2022
Design and in vivo characterization of kidney-targeting multimodal micelles for renal drug delivery
10.1007/s12274-018-2100-2 · 2018
Prescription practices in patients with mild to moderate CKD in India
10.1016/j.ekir.2021.06.011 · 2021
Advances in kidney-targeted drug delivery systems
10.1016/j.ijpharm.2020.119679 · 2020
A review of the application of nanoparticles in the diagnosis and treatment of chronic kidney disease
2020
Improving kidney targeting: the influence of nanoparticle physicochemical properties on kidney interactions
10.1016/j.jconrel.2021.04.016 · 2021
Kidney-targeted redox scavenger therapy prevents cisplatin-induced acute kidney injury
2021
Impact of particle elasticity on particle-based drug delivery systems
10.1016/j.addr.2016.01.007 · 2017
Effect of the surface modification, size, and shape on cellular uptake of nanoparticles
10.1002/cbin.10459 · 2015
Size, surface charge, and shape determine therapeutic effects of nanoparticles on brain and retinal diseases
10.1016/j.nano.2015.04.015 · 2015
Size and shape effects in the biodistribution of intravascularly injected particles
10.1016/j.jconrel.2009.10.014 · 2010
Impact of nanotechnology on drug delivery
10.1021/nn900002m · 2009
Application of nanoparticles in the diagnosis and treatment of chronic kidney disease
2023
Targeted therapy of kidney disease with nanoparticle drug delivery materials
2024
Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery
10.1002/adma.201104763 · 2012
Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines
10.1186/1477-3155-9-55 · 2011
Nanotechnology for the environment and medicine
10.2174/1389557515666150709105129 · 2016
Image‐guided tumor surgery: the emerging role of nanotechnology
10.1002/wnan.1624 · 2020
Strategic use of nanotechnology in drug targeting and its consequences on human health: a focused review
2019
The role of nanomedicine and artificial intelligence in cancer health care: individual applications and emerging integrations—a narrative review
10.1007/s12672-025-02469-4 · 2025
From bits to atoms: machine learning and nanotechnology for cancer therapy
10.26502/jnr.2688-85210042 · 2024
Artificial intelligence in chronic kidney diseases: methodology and potential applications
10.1007/s11255-024-04165-8 · 2025
Artificial intelligence-assisted design of nanomedicines for breast cancer diagnosis and therapy: advances, challenges, and future directions
10.1007/s12668-025-01980-w · 2025
Harnessing artificial intelligence for enhanced nanoparticle design in precision oncology
10.3934/bioeng.2024026 · 2024
Convergence of nanotechnology and artificial intelligence in the fight against liver cancer: a comprehensive review
10.1007/s12672-025-01821-y · 2025
Artificial intelligence in revolutionizing kidney care and beyond: Kid-AI revolution
2024
Nanomedicines for renal disease: current status and future applications
10.1038/nrneph.2016.156 · 2016
Nanomaterials for targeted therapy of kidney diseases: strategies and advances
2025
Renal clearance of quantum dots
10.1038/nbt1340 · 2007
Empagliflozin in patients with chronic kidney disease
10.1056/nejmoa2204233 · doi-reference
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
10.1093/eurheartj/ehab777 · doi-reference
Rationale and protocol of the Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
10.1093/ndt/gfz290 · doi-reference
MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1
10.1186/s13046-019-1490-7 · doi-reference
Quality and safety considerations for therapeutic products based on extracellular vesicles
10.1007/s11095-024-03757-4 · doi-reference
The effect of micro-particle curcumin on chronic kidney disease progression: the MPAC-CKD randomized clinical trial
10.1093/ndt/gfad037 · doi-reference
Micelles with ultralow critical micelle concentration as carriers for drug delivery
10.1038/s41551-018-0234-x · doi-reference
Liposomes and extracellular vesicles as drug delivery systems: a comparison of composition, pharmacokinetics, and functionalization
10.1002/adhm.202100639 · doi-reference
A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives
10.3390/molecules27041372 · doi-reference
Exploring various techniques for the chemical and biological synthesis of polymeric nanoparticles
10.3390/nano12030576 · doi-reference
Polymeric nanoparticles for drug delivery
10.1021/acs.chemrev.3c00705 · doi-reference
Challenges facing sterilization and depyrogenation of nanoparticles: effects on structural stability and biomedical applications
10.1016/j.nano.2014.03.017 · doi-reference
Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities
10.1016/j.drudis.2018.01.047 · doi-reference
Gold nanoparticles for monitoring of mesenchymal stem-cell-loaded bioresorbable polymeric wraps for arteriovenous fistula maturation
10.3390/ijms241411754 · doi-reference
Rosuvastatin-Eluting gold-nanoparticle-loaded perivascular wrap for enhanced arteriovenous fistula maturation in a murine model
10.1007/s42765-023-00315-2 · doi-reference
Bindarit encapsulated nanoparticles prevent venous neointimal hyperplasia and restenosis in a murine angioplasty model
10.1016/j.trsl.2022.06.002 · doi-reference
Adventitial delivery of nanoparticles encapsulated with 1α, 25-dihydroxyvitamin D3 attenuates restenosis in a murine angioplasty model
10.1038/s41598-021-84444-x · doi-reference
1α,25-Dihydroxyvitamin D(3) encapsulated in nanoparticles prevents venous Neointimal Hyperplasia and stenosis in porcine arteriovenous fistulas
10.1681/asn.2020060832 · doi-reference
Bismuth-infused perivascular wrap facilitates delivery of mesenchymal stem cells and attenuation of neointimal hyperplasia in rat arteriovenous fistulas
10.1016/j.bioadv.2024.214052 · doi-reference
Controlled delivery of rosuvastatin or rapamycin through electrospun bismuth nanoparticle-infused perivascular wraps promotes arteriovenous fistula maturation
10.1021/acsami.4c06042 · doi-reference
siRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA
10.1089/nat.2014.0505 · doi-reference
Resveratrol-loaded nanoparticles conjugated with kidney injury molecule-1 as a drug delivery system for potential use in chronic kidney disease
10.2217/nnm-2017-0256 · doi-reference
Improved oral bioavailability and anti-chronic renal failure activity of chrysophanol via mixed polymeric micelles
10.1080/02652048.2020.1849440 · doi-reference
Incorporating zeolitic-imidazolate framework-8 nanoparticles into kidney scaffolds: a first step towards innovative renal therapies
10.1039/d2nr04246k · doi-reference
Nanoparticle-mediated Klotho gene therapy prevents acute kidney injury to chronic kidney disease transition through regulating PPARα signaling in renal tubular epithelial cells
10.1016/j.biomaterials.2024.122926 · doi-reference
Extended-release of therapeutic microRNA via a host-guest supramolecular hydrogel to locally alleviate renal interstitial fibrosis
10.1016/j.biomaterials.2021.120902 · doi-reference
Glutaminase-responsive nano-carrier for precise rejuvenation of senescent cells by restoring autophagy in chronic kidney disease treatment
10.1016/j.ijpharm.2025.125469 · doi-reference
Engineered extracellular vesicle-encapsulated CHIP as novel nanotherapeutics for treatment of renal fibrosis
10.1038/s41536-024-00348-0 · doi-reference
Delivery of nitric oxide with a pH-responsive nanocarrier for the treatment of renal fibrosis
10.1016/j.jconrel.2022.12.059 · doi-reference
A pH-Responsive system based on fluorescence enhanced gold nanoparticles for renal targeting drug delivery and fibrosis therapy
10.2147/ijn.s260069 · doi-reference
Oral delivery of nanomedicine for genetic kidney disease
10.1093/pnasnexus/pgae187 · doi-reference
Quercetin liposomes ameliorate streptozotocin-induced diabetic nephropathy in diabetic rats
10.1038/s41598-020-59411-7 · doi-reference
Targeted delivery of celastrol to renal interstitial myofibroblasts using fibronectin-binding liposomes attenuates renal fibrosis and reduces systemic toxicity
10.1016/j.jconrel.2020.01.017 · doi-reference
Tubule-specific protein nanocages potentiate targeted renal fibrosis therapy
10.1186/s12951-021-00900-w · doi-reference
Enhanced glomerular transfection by BMP7 gene nanocarriers inhibits CKD and promotes SOX9-dependent tubule regeneration
10.1016/j.nantod.2024.102545 · doi-reference
Small-sized cationic miRi-PCNPs selectively target the kidneys for high-efficiency antifibrosis treatment
10.1002/adhm.201800558 · doi-reference
Oral delivery of metformin by chitosan nanoparticles for polycystic kidney disease
10.1016/j.jconrel.2020.10.047 · doi-reference
TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods
10.1136/bmj-2023-078378 · doi-reference
Evaluation of clinical prediction models (part 1): from development to external validation
10.1136/bmj-2023-074819 · doi-reference
Rational design of safer inorganic nanoparticles via mechanistic modeling-informed machine learning
10.1021/acsnano.5c03590 · doi-reference